-
2020년 표적치료연구회 춘계심포지엄
일시 : 2020년 3월 28일 (토)
장소 : 부산 BEXCO, 1층 제2전시장
연수평점 : 3점
사회: 엄중섭(부산의대)
| Time | Title | Speaker & Chairperson |
|---|---|---|
| 11:30 ~ 11:50 | Registration | |
| 11:50 ~ 11:55 | Greeting | 김영태 (대한폐암학회이사장) |
| 11:55 ~ 12:00 | Opening address | 이민기 (표적치료연구회장) |
| 12:00 ~ 12:40 | Luncheon symposium ONO Pharma Korea / BMS |
이민기 (부산의대) |
| Nivolumab, 5 year OS outcome of CheckMate 017/057 and real world outcome in Korea | 김미현 (부산의대) | |
| 12:40 ~ 13:00 | Coffee Break | |
| 13:00 ~ 14:30 | Session I. Clinical consideration for unmet needs in clinical practice |
인광호 (고려의대), 김영태 (서울의대) |
| 13:00 ~ 13:20 | Hyperprogression or pseudoprogression in immune checkpoint inhibitor treatment, that is the question | 박철규 (전남의대) |
| 13:20 ~ 13:40 | Updates of clinical and biomarkers for immune check point inhibitors treating NSCLC | 유승수 (경북의대) |
| 13:40 ~ 14:00 | Drug agonistic acquired resistance in target therapy, is that a clue for outcome improvement? | 윤성훈 (부산의대) |
| 14:00 ~ 14:20 | Sequential treatment issues of target therapy in EGFR or ALK+ NSCLC | 이승현 (부산의대) |
| 14:20 ~ 14:30 | Q & A | |
| 14:30 ~ 15:00 | Coffee Break | |
| 15:00 ~ 15:50 | Session II. NSCLC harboring an NTRK gene fusion |
이계영 (건국의대) |
| 15:00 ~ 15:20 | Pathogenesis, clinicopathologic feature, and diagnosis of NTRK fusion+ NSCLC | 김태정 (가톨릭의대) |
| 15:20 ~ 15:40 | Treatment of NTRK fusion+ NSCLC | 이명규 (연세의대) |
| 15:40 ~ 15:50 | Q & A | |
| 15:50 ~ 16:50 | Session III. NSCLC harboring KRAS mutations |
김영철 (전남의대), 손춘희 (동아의대) |
| 15:50 ~ 16:10 | Emerging target agents for KRAS+ NSCLC | 김인애 (건국의대) |
| 16:10 ~ 16:30 | Efficacy of immune check point inhibitors for KRAS+ NSCLC | 박지영 (한림의대) |
| 16:30 ~ 16:40 | Q & A | |
| 16:40 ~ 16:50 | Interim report of granted KASTT research | 이승룡 (고려의대) |
| 17:00 |
Closing | |